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Summary
Venous malformations (VMs) are localized defects of
vascular morphogenesis. They can occur in every organ
system, most commonly in skin and muscle. They can
cause pain and bleeding, and in some critical locations
they can be life threatening. Usually venous anomalies
occur sporadically, but families with dominant inheri-
tance have been identified. Using linkage analysis, we
have established in earlier reports that some families
with inherited VMs show linkage to chromosome 9p21;
the mutation causes ligand-independent activation of an
endothelial cell–specific receptor tyrosine kinase, TIE-2.
Here we show that VMs with glomus cells (known as
“glomangiomas”), inherited as an autosomal dominant
trait in five families, are not linked to 9p21 but, instead,
link to a new locus, on 1p21-p22, called “VMGLOM”
(LOD score 12.70 at recombination fraction .00). We
exclude three known positional candidate genes, DR1
(depressor of transcription 1), TGFBR3 (transforming
growth factor–b receptor, type 3), and TFA (tissue fac-
tor). We hypothesize that cutaneous venous anomalies
(i.e., glomangiomas) are caused by mutations in a novel
gene that may act to regulate angiogenesis, in concert
with the TIE-2 signaling pathway.
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Introduction
Patients with venous malformations (VMs) are the most
common referrals to centers for vascular anomalies. The
prevalence of this developmental vascular anomaly is not
known (for a review, see Vikkula et al. 1998). VMs
(MIM 600195) are composed of dysmorphic, tortuous,
spongelike veins that present as bluish swellings. The
thin-walled vascular channels are composed of a defi-
cient layer of smooth-muscle cells and are lined by qui-
escent endothelium (Vikkula et al. 1996, 1998). These
lesions can be single or multiple, varying in size from a
small bluish cutaneous spot to an extensive abnormality
affecting deep soft tissues in any part of the body. Clin-
ical management is often difficult and is best directed by
an interdisciplinary team (Enjolras and Mulliken 1996).
As is true for many vascular anomalies, these lesions
may be obvious at birth or may appear later in life. There
is often confusion in the diagnostic terminology of these
lesions; typically they are mistakenly called “cavernous
hemangioma” (Enjolras and Mulliken 1996; Vikkula et
al. 1998). A biological classification, based on clinical
and histological criteria, clearly distinguishes two major
types of vascular anomalies: tumors (usually heman-
gioma) and malformations (Mulliken 1997).
In the past, venous anomalies were considered non-
hereditary; however, there is mounting evidence that
they can be inherited in a Mendelian manner (Boon et
al. 1994; Vikkula et al. 1996). Typically, the affected
individuals in these families have multiple small cuta-
neous lesions. The age at onset is usually !8 years; how-
ever, some patients first manifest these lesions during
puberty. There is variable expressivity in terms of size
and location of the lesions (see Boon et al. 1994).
“Glomangiomas” (MIM 138000) are a clinical and
radiological subtype of VMs (Gorlin et al. 1960) (fig. 1,
top). Their pathognomonic characteristic is the presence
of undifferentiated smooth-muscle cells (glomus cells)
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Figure 1 Top, Typical cutaneous venous malformation with glomus cells (i.e., glomangioma) (arm of individual F-6). Bottom, Histology
of lesion in F-1005, showing anomalous venous channels. Poorly differentiated smooth-muscle cell–like glomus cells (arrows), with typical
rounded nuclei (C and D), are positive for smooth-muscle a-actin (brownish color in B and D). A and C, Results of staining with hematoxylin-
eosin. B and D, Results of immunohistochemical staining with antibody against SMC a-actin.
surrounding convoluted venous channels (Gorlin et al.
1960; Goodman and Abele 1971) (fig. 1, bottom). Clin-
ically, glomangiomas look like any VM; however, they
are more painful on palpation. In contrast to common
VMs, glomangiomas are only partially compressible,
and they are usually not found in mucosa. In addition,
familial aggregation is more common, and several ped-
igrees showing autosomal dominant inheritance have
been described (Touraine et al. 1936; Rudolph 1993;
Iqbal et al. 1998). Penetrance is estimated to rise from
70% at age 5 years to 100% by age 30 years (Iqbal et
al. 1998).
We have previously described, in a large family with
autosomal dominant inheritance, cutaneous and mu-
cosal VMs that cosegregated with markers on chro-
mosome 9p21 (Boon et al. 1994) and that were caused
by a single nucleotide change leading to an R849W sub-
stitution in the endothelial cell–specific receptor tyrosine
kinase, TIE-2 (MIM 600221) (Vikkula et al. 1996). This
mutation results in an increase in receptor autophos-
phorylation (Vikkula et al. 1996) and alters downstream
signaling (Korpelainen et al. 1999). Here we show that
five families with inherited cutaneous VMs with glomus
cells (i.e., glomangiomas) do not show linkage to the
TIE-2 gene (VMCM-1) but, instead, show linkage to a
new locus, VMGLOM, on 1p21-22 (LOD score 12.70
at recombination fraction (v) .00). The minimal region
spans 4–6 cM and is estimated to contain 200 genes.
Six of these genes are already known, and we have ex-
cluded three of the latter: DR1 (depressor of transcrip-
tion 1), TGFBR3 (transforming growth factor–b recep-
tor, type 3), and TFA (tissue factor). We propose that
the VMGLOM gene is important for the proper devel-
opment/maintenance of veins and that it may act in con-
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cert with TIE-2–dependent signaling. We conclude that
separate loci are involved in the ethiopathogenesis of
familial cutaneomucosal VMs and glomangiomas.
Families and Methods
Families and Histochemistry of Lesions
After informed consent was obtained, a clinical his-
tory was taken, and physical examination was per-
formed on all family members participating in the study.
Venous-blood samples were drawn for extraction of
DNA. An additional sample was drawn, for lymphocytic
transformation, from each of individuals Bl-11, Bl-103,
Bl-105, Bt-12, Bt-103, Sh-2, Sh-12, and Sh-101. The
pedigrees are shown in figure 2. Family F has been de-
scribed in detail elsewhere (Rudolph 1993).
Immunohistochemical analysis of 5-mm sections was
performed as described elsewhere (Vikkula et al. 1996;
Stratmann et al. 1998), by means of a primary mono-
clonal antibody against human SMC aactin (1:300;
Dako) and a biotinylated secondary antibody (sheep
anti-mouse IgG, 1:500 dilution; Boehringer Mannheim).
After incubation with streptavidin-peroxidase complex,
3-amino-9-ethyl-carbazole (Boehringer Mannheim) was
used for color detection of immunoreactivity.
Linkage Analysis
Genomic DNA was extracted from the buffy coat
(Qiagen DNA extraction kit). Genotyping of individuals
was performed as described elsewhere (Boon et al.
1994). Polymorphic markers D9S161, D9S169, and
D9S171 were used for analysis of chromosome 9. For
chromosome 1, several markers were selected either
from the Weber 6.0 primer set (Research Genetics) or
on the basis of their map positions (Centre d’E´tude du
Polymorphisme Humain and Cooperative Human Link-
age Center) (synthesized by Gibco-BRL). Linkage anal-
yses were performed under the following assumptions:
dominant mode of inheritance, 1/10,000 disease-allele
frequency, and equal allele frequencies for markers. For
marker D1S188, calculations were also done under the
assumption of 1/100,000 disease-allele frequency with
published allele frequencies. Penetrances of 90% and
100% were used for individuals 116 years of age. The
three unaffected individuals !16 years of age were as-
signed to liability classes with either 80% penetrance
(individuals Sh-100, age 13 years; and T-1006, age 11
years) or 70% penetrance (T-1005, age 5 years). Cal-
culations were performed with Linkage Package version
5.1 (Web Resources of Genetic Linkage Analysis) (La-
throp et al. 1984).
Candidate-Gene Analysis
To screen the DR1 and TFA genes for mutations,
primers (synthesized by Gibco-BRL) were designed ac-
cording to known intronic sequences. Primer pairs P1
and P8, P9 and P10, and P11 and P6 were used for the
DR1 gene (Rozet et al. 1996), and 13 primers were
designed for the TFA gene, according to the published
sequence (GenBank J02846).
The size of the amplification products was 206–301
bp. For SSCP and heteroduplex analysis, both PCR
primers were end-labeled with g-[32P] with use of pol-
ynucleotide kinase (TAKARA), according to manufac-
turer’s recommendations. The PCR reactions were di-
vided into two aliquots before the latter were loaded
onto nondenaturing polyacrylamide gels (MDE gel so-
lution; FMC). EDTA (final concentration 5 mM), and
nondenaturing loading buffer (according to FMC) was
added to the reactions for heteroduplex analysis,
whereas a denaturing loading buffer (according to FMC)
was added to the SSCP samples. After heat denaturation,
the samples for SSCP analysis were immediately loaded
onto SSCP gels. The samples for heteroduplex analysis
were first cooled from 95C to 37C, at 1C/min, to
increase the formation of heteroduplexes. Both gels were
run for 14–16 h, with SSCP gels at constant power (6–8
W) and with heteroduplex gels at constant potential
(700 V). Gels were vacuum-dried and were exposed, for
12–24 h, to KODAK X-Omat film. Fragments showing
abnormal migration were reamplified, purified (Qiagen
PCR columns), and cycle sequenced (Gibco cycle-se-
quencing kit).
To screen the TGFBR3 gene for mutations, cDNA was
synthesized from total RNA extracted from Epstein-Barr
virus–transformed lymphoblasts, as described elsewhere
(Vikkula et al. 1996). Nested PCR reactions were per-
formed in a total volume of 10 ml. Forty PCR primers
were designed (on the basis of the published sequence
[GenBank L07594]). The first-round PCRs amplified the
cDNA in two overlapping pieces, and the second-round
PCR amplified 15 overlapping fragments of 220–288 bp.
PCR conditions were as described elsewhere (Vikkula et
al. 1995).
Southern blot hybridizations were performed with
amplified fragments of the DR1 and TGFBR3 genes as
probes (prepared with primer pair P1 and P6, for the
DR1 gene, and primer pairs TGFBR3-1 and -7 and
TGFBR3-4 and -40, for the TGFBR3 gene). The DNA
fragments were radiolabeled by random priming with
Klenow (GIBCO-BRL), with a-[32P] (ICN), to a specific
activity of . Unincorporated nucleotides were81–2# 10
removed with Micro Bio-Spin columns (Bio-Rad). Five
micrograms each of genomic DNA from Bl-103, Bl-105,
Bt-12, Bt-103, Sh-2, Sh-12, F-105, F-108, T-101, T-
1010, and an unaffected control were digested with ei-
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Figure 2 Pedigrees of five families with inherited VMs with glomus cells. Genotypes for markers in the VMGLOM region are depicted
beneath the symbols representing individuals in the pedigrees. The haplotype cosegregating with the disorder is boxed, and markers in the
linked region are boldface. Circles represent females, and squares denote males; affected individuals are denoted by blackened symbols, and
unaffected individuals are denoted by unblackened symbols. A diagonal slash (/) through a symbol indicates that the individual is deceased.
ND  not determined.
ther EcoRI, PvuII, or HindIII, according to the manu-
facturer’s recommendations (Pharmacia), were sepa-
rated on 0.7% agarose gels, and were transferred, for
Southern blot hybridization, onto Hybond N
membrane (Amersham). The membrane was hybridized
at 42C (in a Techne HB-1D oven), with 50 ml of hy-
bridization solution containing , 50 mM6# SSC
Na2HPO4/NaH2PO4 (pH 6.8), 50% deionized formam-
ide, 50 mg dextran sulfate/ml, 25 mg ssDNA/ml, 1 mM
EDTA (pH 8.0), 0.5% SDS, and solu-1#Denhardt’s
tion (0.02% BSA, 0.02% Ficoll, and 0.02% polyvinyl-
pyrrolidone). After being washed with and0.1# SSC
0.1% SDS at room temperature (four times for 5 min
each) and at 55C (three times for 30 min each), the
filters were exposed, for 12–24 h to KODAK X-OMAT
film.
Results
Families and Histochemistry of Lesions
Affected individuals in all five families had localized
cutaneous venous lesions, clinically similar to those in
affected members of the two families showing linkage
to the TIE-2 gene on 9p21 (fig. 1, top). The size of the
lesions varied from small blue spots (1–5 mm in di-
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ameter) to larger spongy masses (as large as 20 cm in
diameter). The lesions were scattered, and the number
per affected individual was 1–17. In 50% of patients,
the lesions were painful, especially on palpation and/or
at pubertal onset. There were no mucosal lesions. The
age at appearance of the first lesion varied, from birth
to puberty. Thirty percent of the affected individuals had
noted gradual enlargement of their lesions, and 40%
reported an increase in number. Eleven patients had un-
dergone resection of one or more painful lesions. We
obtained two of these tissue samples, one from individ-
ual Bl-1000 and one from individual F-1005. Histolog-
ically, the lesions were composed of malformed veins
with variable numbers of glomus cells (Rudolph 1993)
(fig. 1, bottom). The presence of glomus cells in such
cutaneous venous anomalies is pathognomonic for the
diagnosis of “multiple glomangiomas” or “glomus tu-
mors” (Gorlin et al. 1960).
Exclusion of TIE-2 Gene (VMCM-1)
Because these cutaneous venous lesions were similar
to those in the families with a TIE-2 mutation (Boon et
al. 1994; Vikkula et al. 1996), we first tested the five
families for linkage to chromosome 9p. In each of the
families, one or more affected individuals were recom-
binant for markers on both sides of the TIE-2 gene. The
combined LOD scores ( , penetrance 90%) werev  .00
16.1 for D9S171, 24.1 for D9S169, and 23.4 for
D9S161; the v values for combined LOD scores !2.00
were .20, .20, and .10, respectively. The order of these
markers was D9S171, TIE-2, D9S169, D9S161. These
results clearly exclude a mutation in the TIE-2 gene in
these families and indicate that there must be locus het-
erogeneity for familial VMs.
Linkage to 1p21-22
Having excluded the TIE-2 gene in the five families,
we next tested the TIE-2 homologue TIE-1 on human
chromosome 1p33-34. TIE-1 is an orphan receptor also
known to be important for angiogenesis, because Tie-
1/ murine embryos exhibit severe mesenchymal hem-
orrhage by embryonic day 18.5 (Sato et al. 1995). How-
ever, markers around the TIE-1 gene excluded this locus
(D1S193, D1S447, D1S451, andD1S213 had combined
two-point LOD scores !2.00). Therefore, we started
random screening of the genome, with polymorphic
markers on both the short arm and the centromeric
portion of the long arm of chromosome 1, and identified
a region in which several markers for all five families
gave combined LOD scores 13.0 (see table 1). Thus, the
random screening was discontinued, and no other chro-
mosomes were tested. Changing the disease-allele fre-
quency (1/10,000 or 1/100,000), marker-allele frequen-
cies (equal or published), and penetrances (90% or
100%) did not significantly alter the LOD scores. The
highest combined LOD score was for marker D1S188:
with 90% penetrance and 1/10,000 disease-allele fre-
quency, it reached 12.70 ( ) with published allelev  .00
frequencies and 12.42 ( ) with equal allele fre-v  .00
quencies. If 100% penetrance and published allele fre-
quencies were used for all individuals, the LOD score
increased to 13.58 ( ). Three of the five familiesv  .00
gave maximum positive LOD scores (all informative
meioses) with this marker at . The LOD scoresv  .00
(penetrance 90%) were 2.97 (family Bl), 4.27 (family
F), and 1.82 (family Sh). The other two families also
had positive LOD scores with this marker: 1.91, max-
imum 2.21 (family Bt); and 1.45, maximum 2.39 (family
T). Several other markers on both sides of D1S188 also
showed positive LOD scores in all five families, although
not all individuals were informative for all markers (ta-
ble 1).
To define the borders of the linked interval, we created
haplotypes based on the database order of the markers
(Centre d’E´tude du Polymorphisme Humain and Co-
operative Human Linkage Center). This haplotypic anal-
ysis identified obligatory recombinations at the telomeric
border of the region between markers D1S2627 and
D1S1618 (Bl-106; unaffected), between markers
D1S226 and D1S464 (Sh-10 and -11; both unaffected),
between AFMA205XD5 and D1S435 (F-109; unaf-
fected), and between D1S2627 and D1S435 (T-1001;
affected) (see fig. 2). Obligatory recombinations at the
centromeric end of the linked interval were observed
between markers D1S236 and D1S2775 (Bl-1000; af-
fected), between markers D1S2664 and D1S497 (Sh-10,
-11, and -12; all unaffected), between markersD1S2775
and D1S497 (Bt-103; affected), and between markers
D1S420 and D1S206 (F-108; affected) (fig. 2). Since we
did not have DNA from the deceased affected grand-
father (Bt-2) in family Bt, the three affected daughters
(Bt-10, -12, and-14) were not fully informative for any
of the markers in the region. However, since Bt-14 was
recombinant for marker AFMA205XD5 and markers
telomeric to this marker, the region linked to the phe-
notype reached, at a maximum, to AFMA205XD5. In
the aggregate, the haplotype data defined a minimal re-
gion of overlap between markers D1S2775 and
AFMA205XD5 (fig. 3). On the basis of the linkage maps
(Centre d’E´tude du Polymorphisme Humain and Co-
operative Human Linkage Center) and the MIT YAC-
contig map (Whitehead Institute for Biomedical Re-
search/MIT Center for Genome Research), this interval
is ∼4–6 cM, approximately equivalent to 4–6 Mb.
Exclusion of Positional Candidate Genes
The region under study is estimated to contain 200
genes. On the basis of the human linkage, physical, and
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Table 1
LOD Scores for Markers at VMGLOM, for DiseaseAllele Frequency .0001,
Equal Allele Frequencies, and 90% Penetrance
MARKER
v  .00 v  .01 v  .10 v  .20 v  .30 v  .40
Two-Point LOD Score for Family F
D1S1618 3.76 1.06 .13 .06 .11 .07
D1S2627 1.67 1.63 1.29 .90 .53 .22
AFMA205XD5 1.65 1.64 1.45 1.12 .73 .35
D1S435 4.07 3.40 3.30 2.46 1.56 .65
D1S188 4.27 4.20 3.49 2.66 1.76 .83
D1S424 2.01 1.98 1.63 1.22 .78 .36
D1S236 2.86 2.82 2.40 1.87 1.27 .63
D1S2775 1.88 1.85 1.57 1.21 .81 .40
D1S2664 2.70 2.63 2.01 1.33 .72 .25
D1S497 1.83 1.81 1.53 1.15 .75 .35
D1S420 3.77 3.70 3.04 2.25 1.41 .57
D1S206 2.52 .43 1.01 .83 .53 .24
Combined LOD Scores for Five Families with Inherited
VMs with Glomus Cellsa
D1S1618b 7.90 1.58 .44 .68 .52 .26
D1S2627b .08 5.00 4.89 3.77 2.40 1.04
AFMA205XD5b .60 1.38 2.09 1.82 1.27 .62
D1S435 9.62 9.47 7.92 5.95 3.79 1.60
D1S188 12.42 12.22 10.23 7.73 5.01 2.26
D1S424 8.26 8.13 6.80 5.09 3.22 1.39
D1S236 8.23 8.12 6.92 5.33 3.55 1.65
D1S2775 1.07 2.18 2.58 2.06 1.36 .62
D1S2664 4.68 7.47 6.58 4.72 2.79 1.10
D1S497 .82 4.86 5.43 4.31 2.87 1.33
D1S420 1.60 4.73 5.34 4.24 2.74 1.18
D1S206c 5.33 .62 1.99 1.71 1.08 .42
a Penetrance for T-1005 was 70%; penetrance for Sh-100 and T-1006 was 80%.
b No data were available for family Sh.
c No data were available for family Bt.
transcript maps, six of these are known; one of the latter,
ABCR (ATP-binding–cassette transporter) is mutated in
Stargardt disease (MIM 248200) and thus was excluded
as a candidate gene for VMs with glomus cells. Because
of their known function, we also considered the genes
encoding ribosomal protein L5 (RPL5) and ggluta-
mylcysteine synthetase (GLCLR) to be unlikely candi-
dates. The three remaining genes could not be excluded
as positional candidates, on the basis of current infor-
mation. Therefore, we screened the coding sequences of
these genes, for rearrangements and nucleotide changes,
by SSCP, heteroduplex analysis, and Southern blot hy-
bridizations in families Bl, Bt, and Sh.
Southern blot hybridization of the three positional
candidate genes—DR1, TFA, andTGFBR3—showed no
evidence for genomic rearrangements or deletions. SSCP
screening for the DR1 and TFA genes revealed only a
known polymorphism, in exon 3 in theDR1 gene (Rozet
et al. 1996), and polymorphism of an extra G, in the
sequence of intron 5 of the TFA gene (position 10262;
GenBank J02846).
SSCP screening of the full-length cDNA of the
TGFBR3 gene showed three nucleotide polymorphisms:
G563rA (PstI), G1548rA, and C2370rT (GenBank
L07594). The three positional candidate genes were also
screened for altered nucleotides by heteroduplex anal-
ysis, but only one additional DNA sequence change was
identified, a G2918rA (MspI) polymorphism in the
TGFBR3 gene. None of these changes either cause an
amino acid substitution or, even if identified in patients,
segregate with the phenotype, implying that they reside
on the unlinked allele.
In addition to these polymorphisms, we found three
nucleotides (C at location 555 and GG at location 564)
missing from the published TGFBR3 sequence (Gen-
Bank L07594), both an extra G (position 2909) and a
missing G (position 2955) in the same TGFB3R se-
quence, and 52 bp of intronic sequence that is not iden-
tified in the published DR1 sequence (Rozet et al. 1996).
These changes were also found in control individuals
and therefore represent mistakes in the published
sequences.
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Figure 3 Schematic map of VMGLOM region. Marker order is
based on the MIT physical map (Whitehead Institute for Biomedical
Research/MIT Center for Genome Research). Positions of the TIE-1
gene and five known genes in VMGLOM are also shown: TGFBR3,
RPL5, DR1, ABCR, GLCLR, and TFA. Numbers in boldface italic
are distances (in cM) from 1pter. The vertical bars with identification
numbers for recombinant individuals (fig. 2) show the linked regions
in the families.
Discussion
VMs are developmental in origin, and, if extensive,
they are difficult to treat (Mulliken and Young 1988).
They are composed of convoluted thin-walled vascular
channels with deficient intramural smooth muscle. A
mutation in the TIE-2 gene causes one familial type of
mucocutaneous VM (Vikkula et al. 1996). The identified
substitution, R849W in two families, causes ligand-in-
dependent autophosphorylation of the receptor (Vikkula
et al. 1996). In addition, the mutant receptor activates
STAT1 signaling, normally not activated by wild-type
TIE-2 (Korpelainen et al. 1999).
The affected individuals in the five families described
in the present study had lesions clinically similar to the
cutaneous VMs in the families showing linkage to TIE-
2, although they were typically painful on palpation. No
mucosal lesions were noted in these five families. The
distinctive glomus cells also differentiated these lesions.
As in patients with the R849W TIE-2 mutation, lesions
in the five families described in the present study evi-
denced variable expressivity in size, location, and num-
ber. A high (98%) penetrance was observed for the mu-
tation in the TIE-2 gene (Vikkula et al. 1996). Since the
phenotype never skipped a generation in the five families
and since 34/61 (55.7%) of the children of affected in-
dividuals had venous lesions, the penetrance can be as-
sumed to be high in these families too. Of the 38 affected
individuals, 18 (47.3%) were males, and male-to-male
transmission was found in four of the pedigrees. Thus,
the inheritance seems to be autosomal dominant, with
(nearly) 100% penetrance and without sex influence.
Using linkage analysis, we identified a locus, called
“VMGLOM,” on chromosome 1p21-22. Several mark-
ers showed high combined positive LOD scores (table
1). Varying gene frequencies and allele frequencies in the
linkage calculations did not significantly alter the LOD
scores. With three liability classes, of 90%, 80%, and
70% penetrance, respectively, the maximum LOD score
was 12.70 ( ), and with a single liability class ofv  .00
100% penetrance it was 13.58 ( ). These resultsv  .00
give strong statistical evidence that this chromosomal
region contains a gene that, when mutated, causes VMs
with glomus cells (i.e., glomangiomas).
Haplotype analysis defined the smallest linked interval
at 4–6 cM, between markers AFMA205XD5 and
D1S2775. Possible positional candidate genes are DR1,
TFA, and TGFBR3. DR1 is a depressor of transcription
and could be involved in TIE-2 signaling. In knockout
mice, tissue factor has been shown to be important for
both extraembryonic recruitment of pericytes and vas-
cular development (Bugge et al. 1996; Toomey et al.
1996). TGFb-binding proteins are implicated in another
vascular disorder, hereditary hemorrhagic telangiectasia
(McAllister et al. 1994; Johnson et al. 1996). However,
none of these genes was found mutated in the families
showing linkage to VMGLOM.
Three other known genes are located in the
VMGLOM locus: ABCR, GLCLR, and RPL5. How-
ever, these are unlikely to be the VMGLOM gene(s).
The ABCR gene is mutated in Stargardt macular dys-
trophy (Allikmets et al. 1997). The g-glutamylcysteine
synthetase light subunit is the inhibitory part of a two-
subunit enzyme complex needed for glutathione synthe-
sis; and a deficiency in this catalytic activity has been
linked to hemolytic anemia (Meister 1974). The RPL5
gene is not a strong candidate either, because ribosomal
proteins usually have important functions in a large
number of different cell types.
Since cutaneous VMs and VMs with glomus cells re-
semble one another, it might be assumed that their ethio-
pathogenic mechanisms are similar. Therefore, genes
that interact with the TIE-2 signaling pathway are pos-
sible candidates forVMGLOM. The TIE-2 receptor may
signal via SH-PTP2, GRB2 (Huang et al. 1995), Dok-R
(Jones and Dumont 1998), or AKT, via activation by
p85/PI3-kinase (Kontos et al. 1998) and by STAT3 and
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STAT5 (signal transducers and activators of transcrip-
tion) (Korpelainen et al. 1999). In addition, the R849W
mutant receptor appears to activate STAT1 and, thereby,
p21 (Korpelainen et al. 1999). However, none of the
genes encoding these intracellular substrates localize to
VMGLOM.
Three TIE-2 ligands are known: angiopoietin-1 (MIM
601667), -2, and -4 (ANG-1, -2, and -4) (Davis et al.
1996; Suri et al. 1996; Maisonpierre et al. 1997; Val-
enzuela et al. 1999). However, the genes are located on
8q22.3-q23, 8p23, and 20p13, respectively (Cheung et
al. 1998; Valenzuela et al. 1999). TIE-2–receptor sig-
naling could involve another receptor subunit. This pos-
sibility is supported by the observation that ANG-2 and
ANG-4 exert a cell-type specific effect on TIE-2. They
do not induce TIE-2 autophosphorylation in endothelial
cells, but they do cause TIE-2 activation in fibroblasts
(Maisonpierre et al. 1997; Witzenbichler et al. 1998;
Valenzuela et al. 1999). These findings suggest that fi-
broblasts either express a protein that converts the ANG-
2/ANG-4 effect from negative to positive or they lack a
protein, expressed in endothelial cells, responsible for
the endothelial-specific inhibitory effect of ANG-2 and
ANG-4. A loss-of-function mutation in such a protein
would render TIE-2 susceptible to the activating effects
of ANG-2 and ANG-4. This would be similar to the
activating R849W mutation, in TIE-2, that is responsible
for familial cutaneomucosal VMs (Vikkula et al. 1996).
In summary, there is locus heterogeneity for inherited
cutaneous VMs. Affected individuals in five families with
VMs and glomus cells (i.e., glomangiomas) do not have
mutations in the TIE-2 gene. Instead, the disorder in
these families is linked, with a maximum combined LOD
score of 12.70 ( ), to a second locus, calledv  .00
“VMGLOM,” on chromosome 1p21-22, located be-
tween markers D1S2775 and AFMA205XD5. Three
known positional candidate genes were normal in af-
fected family members. Although the identity of the
VMGLOM gene remains to be discovered, histological
observations suggest that VMGLOM mutations cause
decreased differentiation of smooth-muscle cells in af-
fected veins. Furthermore, the presence of glomus cells
helps to distinguish between families showing linkage to
the TIE-2 gene and families showing linkage to
VMGLOM. The high penetrance observed in these fam-
ilies underscores the likelihood of affected progeny of
affected individuals. This report provides a framework
for testing other families for linkage to the VMGLOM
locus and for positional cloning of the causative gene.
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